{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:27:23Z","timestamp":1777904843851,"version":"3.51.4"},"reference-count":19,"publisher":"Society of Nuclear Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,1,14]]},"published-print":{"date-parts":[[2026,5]]},"DOI":"10.2967\/jnumed.125.271423","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:26:02Z","timestamp":1770913562000},"page":"724-730","source":"Crossref","is-referenced-by-count":1,"title":["Biochemical Recurrence\u2013Free Survival After Radical Prostatectomy in Patients with High-Risk Prostate Cancer: A Nationwide Study of PSMA PET\/CT Versus Conventional Imaging"],"prefix":"10.2967","volume":"67","author":[{"given":"Anna W.","family":"Mogensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Torp-Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"N\u00f8rgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars J.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter B.","family":"\u00d8stergren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helle D.","family":"Zacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1602","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"2026050105301229000_67.5.724.1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1053\/j.semnuclmed.2019.02.004","article-title":"Molecular imaging for primary staging of prostate cancer","volume":"49","author":"Pomykala","year":"2019","journal-title":"Semin Nucl Med."},{"key":"2026050105301229000_67.5.724.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"2026050105301229000_67.5.724.3","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients","volume":"44","author":"Afshar-Oromieh","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026050105301229000_67.5.724.4","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol."},{"key":"2026050105301229000_67.5.724.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-013-2525-5"},{"key":"2026050105301229000_67.5.724.6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00345-018-2182-1","article-title":"68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review","volume":"36","author":"Corfield","year":"2018","journal-title":"World J Urol."},{"key":"2026050105301229000_67.5.724.7","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5534\/wjmh.180124","article-title":"Diagnostic performance of 68Ga labelled prostate-specific membrane antigen positron emission tomography\/computed tomography and magnetic resonance imaging for staging the prostate cancer with intermediate or high risk prior to radical prostatectomy: a systematic review and meta-analysis","volume":"38","author":"Wu","year":"2020","journal-title":"World J Mens Health."},{"key":"2026050105301229000_67.5.724.8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol."},{"key":"2026050105301229000_67.5.724.9","unstructured":"Danish prostate cancer guidelines. Dansk Urologisk Cancer Gruppe website. https:\/\/ducg.dk\/daproca-prostatacancer\/kliniske-retningslinjer. Accessed January 26, 2026."},{"key":"2026050105301229000_67.5.724.10","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-014-9930-3"},{"key":"2026050105301229000_67.5.724.11","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol."},{"key":"2026050105301229000_67.5.724.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04568-1"},{"key":"2026050105301229000_67.5.724.13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.eururo.2023.06.022","article-title":"Presurgical 68Ga-PSMA-11 positron emission tomography for biochemical recurrence risk assessment: a follow-up analysis of a multicenter prospective phase 3 imaging trial","volume":"84","author":"Dja\u00efleb","year":"2023","journal-title":"Eur Urol."},{"key":"2026050105301229000_67.5.724.14","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1080\/0284186X.2022.2129442","article-title":"Recurrence rate after radical prostatectomy following primary staging of high-risk prostate cancer with 68Ga-PSMA PET\/CT","volume":"61","author":"Klingenberg","year":"2022","journal-title":"Acta Oncol."},{"key":"2026050105301229000_67.5.724.15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.euo.2024.11.003","article-title":"Early oncological outcomes in patients who underwent staging prostate-specific membrane antigen positron emission tomography\/computed tomography compared with conventional imaging before radical prostatectomy and extended pelvic lymph node dissection","volume":"8","author":"Ettema","year":"2025","journal-title":"Eur Urol Oncol."},{"key":"2026050105301229000_67.5.724.16","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1097\/RLU.0000000000005284","article-title":"Evaluation of treatment outcomes of prostate cancer patients with lymph node metastasis treated with definitive radiotherapy: comparative analysis of PSMA PET\/CT and conventional imaging","volume":"49","author":"Onal","year":"2024","journal-title":"Clin Nucl Med."},{"key":"2026050105301229000_67.5.724.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.10.011"},{"key":"2026050105301229000_67.5.724.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.08.013"},{"key":"2026050105301229000_67.5.724.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.269996"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.271423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:30:28Z","timestamp":1777638628000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.271423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,1]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.2967\/jnumed.125.271423"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.271423","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}